2024-09-02 - Analysis Report
## LLY Stock Analysis Report

This report provides an analysis of Lilly (LLY) stock, a leading pharmaceutical company known for its innovative treatments across various therapeutic areas. 

**1. Performance vs. S&P 500 (VOO):**

* LLY's cumulative return is 571.94%, significantly outperforming the S&P 500's return of 89.66%. 
* The relative divergence, measuring the gap between LLY and VOO, currently stands at 482.28, indicating that LLY has outperformed the market by a substantial margin. This represents the 100th percentile of historical performance relative to the S&P 500. 

**2. Recent Price Movement:**

* **Closing Price:** $960.02
* **5-day Moving Average:** $950.83
* **20-day Moving Average:** $907.01
* **60-day Moving Average:** $888.73

LLY's current price is above all three moving averages, indicating a strong upward trend. The relatively close proximity of the 5-day moving average to the current price suggests that the upward trend is recent and could continue in the short term.

**3. Technical Indicators:**

* **RSI:** 78.82
* **PPO:** 0.36
* **Delta_Previous_Relative_Divergence:** 18.98  (Positive, suggesting short-term upward momentum)
* **Expected Return:** 0.0% (maximum 5-year expected return based on current investment amount)

The high RSI value indicates that the stock is in overbought territory, potentially suggesting a short-term correction. However, the positive Delta_Previous_Relative_Divergence and PPO value indicate continued short-term bullish momentum. The Expected Return is currently zero, suggesting that while the stock has historically outperformed, future returns may be more modest.

**4. Recent Earnings and Outlook:**

| Date     | EPS      | Revenue     |
|----------|----------|-------------|
| 2024-08-08 | 3.29    | $11.30 B$ |
| 2024-04-30 | 2.49    | $8.77 B$ |
| 2023-11-02 | -0.06   | $9.50 B$ |
| 2023-08-08 | 1.96    | $8.31 B$ |

The latest earnings report for the quarter ended August 8, 2024, showed strong results with an EPS of $3.29 and revenue of $11.30 Billion, exceeding analyst estimates. This demonstrates continued strong performance and growth for the company.  

**5. Overall Analysis:**

Lilly (LLY) is a strong performer, showing consistent outperformance against the broader market.  Despite being in overbought territory, short-term indicators suggest continued upward momentum.  The company's recent earnings demonstrate robust financial performance, further supporting its bullish outlook. However, potential short-term correction risks should be monitored given the high RSI value.

**6. Recommendations:**

* **Long-Term Investment:** LLY remains a strong long-term investment due to its consistent growth, innovative pipeline, and solid financial performance.
* **Short-Term Caution:**  Consider short-term position adjustments given the high RSI value and potential for a pullback, particularly if the price crosses below the 5-day moving average.
* **Monitor Key Metrics:** Closely monitor the company's earnings announcements, future pipeline advancements, and key technical indicators for further decision-making. 
